HOME >> MEDICINE >> NEWS
GSK announces launch of largest ever Phase III trial in lung cancer treatment

Chicago - June 5th, 2007 GlaxoSmithKline (GSK) today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC). These data were presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, [Abstract No: 7554]. Final trial analysis showed a 27% reduction in the relative risk of cancer recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo.

Final results from this trial confirm the positive interim results released last year at ASCO 2006, and support expanded testing of this novel cancer immunotherapy, said Paul A. Bunn Jr., M.D., James Dudley Endowed Professor of Oncology, Professor of Medicine and Director of the University of Colorado Cancer Center, Aurora, Colorado. This approach represents a potentially momentous shift in the cancer treatment paradigm. I believe we have only just scratched the surface of what is possible and look forward to seeing the results of the Phase III trial in due course.

Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3 positive patients with completely resected stage IB, II or IIIA NSCLC.

GSKs ASCIs aim to stimulate the patients own immune response to identify and attack cancer cells in a highly specific manner. This novel cancer immunotherapy is developed using tumor specific antigens, delivered as highly purified recombinant proteins, and GSKs own proprietary Adjuvant Systems, which are specifically designed to enhance ASCIs anti-tumor activity

Phase
'"/>

Contact: Andrea Long
andreal@wagged.com
202-326-0791
GlaxoSmithKline Biologicals
5-Jun-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. AstraZeneca announces SYMBICORT is now available in the US
3. Weill Cornell Medical College announces gifts totaling $400M
4. Elsevier announces launch of Brain Stimulation
5. NSW Premier announces $15M for childrens cancer research
6. National Inventors Hall of Fame announces 2007 inductees
7. Emory University announces new Global Health Institute
8. BioMed Central announces Journal of Medical Case Reports
9. Tibotec Therapeutics announces start of largest US study on HIV treatment in women
10. Wiley announces partnership with NASPGHAN and AASLD
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2019)... ... February 13, 2019 , ... Following the longest federal government ... American Academy of Sleep Medicine (AASM) is warning that such shutdowns exacerbate the ... Transportation Security Administration (TSA) officers. , “Even in typical circumstances, safety may be ...
(Date:2/13/2019)... , ... February 13, 2019 , ... ... 2019, at the company’s annual member conference, Elevate 2019 at the Gaylord Rockies ... staff and members to explore potential partnerships driving improved quality of patient care, ...
(Date:2/13/2019)... ... ... Castle announced today that it has raised $9.2M in Series A funding ... First Round and F-Prime Capital Partners . Angel investors joining the ... Alto Networks, and Olivier Pomel, CEO at Datadog. This round brings the company’s total ...
(Date:2/13/2019)... ... February 13, 2019 , ... Dr. Jig Patel and the ... Merchant, an exceptionally talented and knowledgeable dentist from St. Louis, MO, to ... techniques, such as CEREC same-day dentistry, root canals and emergency treatment. Dr. Patel, Dr. ...
(Date:2/13/2019)... ... 2019 , ... Surgery that moves both jaws forward – known as maxillomandibular ... (OSA), resulting in benefits that include improved breathing, daytime wakefulness and quality of life, ... should be regarded as the preferred treatment for patients with moderate to severe OSA ...
Breaking Medicine News(10 mins):
(Date:2/13/2019)... ... February 13, 2019 , ... The Louisville Men’s Clinic has ... of 2013 and, to date, has been visited by over 20,000 men suffering ... 90% success rate, The Louisville Men’s Clinic prides itself on being on the ...
(Date:2/13/2019)... , ... February 13, 2019 , ... ... innovation expert, will deliver the keynote speech on Wednesday, May 8, at its ... May 6-8 at the Westin Kierland Resort & Spa in Scottsdale, Arizona, and ...
(Date:2/13/2019)... ... February 13, 2019 , ... IMAT Solutions, a ... is launching IMAT 8.0, its latest health data platform, at HIMSS 2019. , ... interface and dynamic single-query builder, IMAT 8.0 allows HIEs, payers, hospitals, clinics, and ...
Breaking Medicine Technology:
Cached News: